According to the U.S. Centers for Disease Control and Prevention (CDC), medications are not taken as prescribed half of the time. After six months, most patients suffering from chronic diseases are taking less medication than prescribed or have stopped taking it altogether.¹

Designing an optimal dose form with advanced delivery technologies is critical to patient acceptance and adherence. From Softgels to Zydis^® fast disintegrating tablets to Modified release, Catalent has a broad range of technologies that can help address challenges that patients face with their treatment.

Join our upcoming webinar to discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes.

To understand the factors that influence the early drug development journey for small molecules, Catalent and a media partner conducted an exclusive survey with participants from the pharma industry. Our industry report explores survey respondents’ opinions on why so many new drugs fail to deliver on their promise, and how they plan to avoid those pitfalls with their own compounds.

To enhance its end-to-end development and delivery Solutions, Catalent has recently expanded its liquid filled hard capsule (LFHC) capabilities, at its St. Petersburg, Florida and Beinheim, France facilities. This LFHC expansion allows selection of an optimal delivery platform for a molecule at any stage of development through commercialization, assuring an efficient development path and robust commercial formulation for complex compounds.